Request Demo
Last update 28 Jun 2025
BI-443651
Last update 28 Jun 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms BI 443651, BI443651 |
Target |
Action blockers |
Mechanism ENaC blockers(Epithelial sodium channel blockers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with BI-443651NCT03135899
A Two Part Phase I, Multiple-dose, Single- and Double-blind, Randomised, Double-dummy, Placebo-controlled, Four-way Crossover Study to Assess Safety and Tolerability of BI 443651 Via Respimat® Versus Placebo Via Respimat® in Subjects With Mild Asthma Following Methacholine Challenge.
NCT02976519
A Phase Ib, Multicentre, Double Blind, Randomized, Two-part Study, First Part Multiple Rising Dose and Second Part Two-way Cross-over, to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of BI 443651 Compared to Placebo Via Respimat® in Healthy Volunteers and CF Subjects.
NCT02706925
Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 443651 in Healthy Male Volunteers in a Partially Randomised, Single Blind, Placebo-controlled Trial
100 Clinical Results associated with BI-443651
Login to view more data
100 Translational Medicine associated with BI-443651
Login to view more data
100 Patents (Medical) associated with BI-443651
Login to view more data
100 Deals associated with BI-443651
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Asthma | Phase 1 | United Kingdom | 18 May 2017 | |
| Cystic Fibrosis | Phase 1 | Germany | 15 Feb 2017 | |
| Cystic Fibrosis | Phase 1 | United Kingdom | 15 Feb 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | 63 | Placebo | etpwcrmdio = zyapsbqjig fpkzxxlbon (cqjncusxbb, qquwdktign - wngjereexk) View more | - | 02 Jan 2020 | |
Phase 1 | 64 | (Placebo Matching BI 443651) | lsywapkdno = vlgkoqgycf bekahnajtv (xoxuvsvabx, qqmuvuzaum - yjcucorril) View more | - | 27 Nov 2019 | ||
(BI 443651 100 Microgram (μg)) | lsywapkdno = dvtzcqvruo bekahnajtv (xoxuvsvabx, ffnvnucdwl - jqvmsmnmiw) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free